To report our first clinical experience with a new continuous ambulatory peritoneal dialysis (CAPD)fiuid (PD-Bio), which is nearly devoid of glucose degradation products and has a higher pH (6.3) than conventional peritoneal dialysis (PD) solutions, and to discuss in general terms some acute and long-term effects of conventional acidic solutions containing glucose degradation products.
Design
1) Pilot study on 4 patients investigated using a modified peritoneal equilibration test (PET) and cytobiology parameters. 2) Computer simulation study, assuming that conventional acidic solutions cause vasodilatation and recruitment of capillary surface area initially (during 0–60 minutes) in a PD dwell.
Patients
Four stable CAPD patients were chosen in an open cross-over study. After a period of three months using conventional PD fluid, the patients were switched to three months on the new PD fluid.
Results
Cancer antigen 125 increased significantly, and patients with discomfort/infusion pain during the control period improved during the period with the new fluid. No significant changes were observed in mass-transfer coefficients or drained volumes with the new solution. PH in the effluent dialysis was, however, higher for PD-Bio at all times during a two-hour dwell. In the computer simulation study, a less acidic solution caused an initially lower rate of glucose dissipation and improved ultrafiltration (UF) after a four -hour dwell, as compared to a conventional PD solution.
Conclusion
A new, differently produced, less toxic and less acidic PD fluid (PD-Bio) seems to be better tolerated than a conventional acidic solution with respect to discomfort/infusion pain. Theoretically, neutralized solutions should show slightly improved UF profiles over conventional acidic solutions, according to the computer simulation analysis. Furthermore, it is speculated that a neutral, less acidic, less toxic fluid would cause less interstitial-mesothelial alterations and less impairment of UF capacity than conventional solutions during longterm CAPD.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminiscence, phagocytosis and bactericidal activity in vitro.Infect Immunity1981; 33: 130–5.
2.
GallimoreB., GagnonR.F., StevensonM.M.Cytotoxicity of commercial peritoneal dialysis solutions towards peritoneal cells of chronically uremic mice.Nephron1986; 43: 288–9.
3.
TopleyN., AlobaidiH.M.M., DaviesM., ColesG.A., WilliamsJ.D.The effects of dialysate on peritoneal phagocyte oxidative metabolism.Kidney Int1988; 34: 404–11.
4.
ManahanF.J., IngB.L., ChanJ.C., GuptaD., ZhouF.Z., PalI.Effects of bicarbonate-containing versus Lactate-containing Peritoneal Dialysis solutions on superoxide production by human neutrophils.Artif Organs1989; 13(6): 495–7.
5.
BronswijkH., VerbrughH.A., BosH.J., HeeziusECJM, van der MeulenJ., VerhoefJ.Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro.Perit Dial Int1989; 9: 197–202.
6.
GouptaD.K., IngB.L., ManahanF.J., ZhouF., YuA.W., NawabZ.M.Superoxide generation byneutrophils after exposure to a conventional peritoneal dialysis solution for different time periods.Artif Kid Dial1990; 13: 228–30.
7.
JörresA., JörresD., GahlG., KesselM., MullerC., KöttgenE.Leukotrine b and tumor necrosis factor release from leucocytes: Effect of peritoneal dialysate.Nephron1991; 58: 276–82.
8.
WieslanderA., NordinM.K., KjellstrandP.T., BobergU.Toxicity of peritoneal dialysis fluids on cultured fibroblasts L-929.Kidney Int1991; 40: 77–9.
9.
KristensenS.R., PedersenF.B.Cytotoxicity testing of two CAPD dialysis fluids in a model system of qui scent fibroblasts.Nephrol Dial Transplant.1993; 8: 163–7.
WieslanderA.P.Cytotoxicity of glucose degradation products in PD fluids [doctoral thesis].Lund (Sweden): Department of Nephrology, University of Lund, 1995.
17.
WieslanderA.P., KjellstrandP.T.T., RippeB.Heat sterilization of glucose-containing fluids for peritoneal dialysis: Biological consequences of chemical alterations. In: Biocompatibility of Peritoneal Dialysis Solutions, Perit Dial Int1995; 7(15): S52–60.
18.
HeimbürgerO., WaniewskiJ., WerynskiA., TranaeusA., LindholmB.Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity.Kidney Int1990; 38: 495–505.
19.
ShawM.W., HayesE.Effects of irradiated sucrose on the chromosomes of human lymphocytes in vitro.Nature1966; 21: 1254–6.
HendersonI.S., CouperI.A., LumsdenA.The effect of shelf life of peritoneal dialysis fluid on ultra filtration in CAPD. In: La GrecaG., ed. Peritoneal dialysis.Milan: Wichtig, 1986: 85–6.
22.
WieslanderA.P., DeppischR., SvenssonE., ForsbäckG., SpeidelR., RippeB.In Vitro biocompatibility of heat a sterilised low-toxic and less acidic fluid for peritoneal dialysis.Perit Dial Int1994; 15: 158–64.
23.
LambE.J., Cat tellW.R., Dawnay AB StJ.In vitro formation of advanced glycation end products in peritoneal dialysis fluid.Kidney Int1995; 47: 1768–74.
24.
RippeB.Pathophysiological description of the ultrastructural changes of the peritoneal membrane during long-term continuous ambulatory peritoneal dialysis.Blood Purif1994; 12: 132–36.
25.
SimonsenO., WieslanderA.P., LandgrenC., RippeB.Less infusion pain and elevated level of CA-125 and by the use of a new and more biocompatible PD fluid. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin1996; 12: 156–60.
RippeB., KredietR.T. In: NolphK.D., GokalR., eds. The textbook of peritoneal dialysis.Kluwer Academic Pub lisher1994; 69–113.
28.
RippeB., StelinG.Simulations of peritoneal solute transport during continuous ambulatory peritoneal dialysis (CAPD). Application of two-pore formalism.Kidney Int1989; 35: 1234–44.
29.
ZakariaE.R., CarlssonO., SjunnessonH., RippeB.Liver is not essential for solute transport during peritoneal dialysis.Kidney Int1996; 50: 298–303.
30.
KredietR.T., StruijkD.G., BoeschotenE.W., HoekF.J., AriszL.Measurement of intraperitoneal fluid kinetics in CAPD patients by means of autologous haemoglobin.Netherlands Journal of Medicine1988; 33: 281–90.
31.
StelinG., RippeB.A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD.Kidney Int1990; 38: 465–72.
32.
KoomenG.C.M., BetjesM.G.H., ZemelD., KredietR.T., HoekF.J.Cancer Antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis.Perit Dial Int1994; 14: 132–6.
33.
VisserC.E., Brouwer-SteenbergeJ.J.E., BetjesM.G.H., KoomenG.C.M., BeelenR.H.J., KredietR.T.Cancer Antigen 125: A bulk marker for the mesothelial mass in stable peritoneal dialysis patients.NephrolDial Transplant1995; 10: 64–9.
34.
ParkM.S., HeimbürgerO., WaniewskiJ., WerynskiA., LeeB.H., BergströmJ.The effect of dialysate acidity on peritoneal solute transport in the rat.Perit Dial Int1995; 15: 312–9.
35.
HeimbürgerO., WaniewskiJ., WerynskiA., LindholmB.A quantitative description of solute and fluid transport during peritoneal dialysis.Kidney Int1992; 41: 1320–32.
36.
RippeB., StelinG., HaraldssonB.Computer simulations of peritoneal fluid transport in CAPD.Kidney Int1991; 40: 315–25.
37.
ComperW.D., LaurentT.C.Physiological function of connective tissue polysaccharides.Physiol Rev1978; 58: 255–315.
38.
ImholzAL T., KoomenG.C.M., StruijkD.G., AriszL., KredietR.T.Fluid and solute transport in CAPD patients using ultralow sodium dialysate.Kidney Int1994; 46: 333–40.
39.
LeypoldtJ.K., CharneyD.I., CheungA.K., NaprestekC.L., AkinB.H., ShockleyT.R.Ultrafiltration and solute kinetics using low sodium peritoneal dialysate.Kidney Int1995; 48: 1959–66.
40.
RippeB., StelinG., HaraldssonB.Understanding the kinetics of peritoneal transport. In: HatanoM., ed. Proceedings of the XIth International Society of Nephrology meeting, Tokyo, 1990.Tokyo: Springer International Inc., 1991; 1563–72.
41.
VoneshE.F., RippeB.Net fluid absorption undermembrane transport models of peritoneal dialysis.Blood Purif1992; 10: 209–26.
42.
YamamotoT., SakakuraT., YamakawaM.Clinical effects of long-term use of neutralized dialysate for continuous ambulatory peritoneal dialysis.Nephron1992; 60: 324–9.
43.
DaugirdasJ.T., ChaudryA.H., IngI.L.Alkalinization of peritoneal dialysis solutions with sodium hydroxide or sodium bicarbonate.ArtifOrgans1995; 12(3): 203–5.
44.
FerianiM., DissegnaD., LaGrecaG., Passlick-DeetjenJ.Short term clinical study with bicarbonate-containing peritoneal dialysis solution.Perit Dial Int1993; 13: 296–301.
45.
TopleyN., JörresA., LuttmannW.Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1β and TNF-α.Kidney Int1993; 43: 226–33.
46.
TopleyN., JörresA., PetersenM.M.Human peritoneal mesothelial cell prostaglandin (PG) metabolism: Induction by cytokines and peritoneal macrophage conditioned medium.J Am Soc Nephrol1991; 2: 432.
47.
BosH.J., StruijkD.G., TukC.W.Peritoneal dialysis induces a local sterile inflammatory state and the mesothelial cells in the effluent are related to the bacterial peritonitis incidence.Nephron1991; 59: 508–9.
48.
DobbieJ.W.Morphology of the peritoneum in CAPD.Blood Purif1989; 7: 74–85.
49.
DobbieJ.W.Durability of the peritoneal membrane. Biocompatibility of Peritoneal Dialysis Solutions.Perit Dial Int1995; 7(15): S87–S92.
50.
ZakariaE.R., RippeB.Intraperitoneal fluid volume changes during peritoneal dialysis in the rat: Indicator dilution versus volumetric measurements.Blood Purif1995; 13: 255–70.
